O BSH recommends new medicines to treat patients with COVID-19

Barcitineb medicine (a type of medicine like the brake Janus kinase [ JAK, which is used to treat rheumatoid arthritis, according to WHO, is recommended to be used to patients who are seriously ill and critical, in combination with cortichosteroids, which are powerful antiflammations drugs and strengthens the immune response.

O The BSH said this recommendation is based on data that suggests that it improves survival prospects and reduces the need for patients to get into the fan and has not been found to cause side effects.

O Experts BSH said barcitineb has similar effects on arthritis, IL-6 brakes (anti-inflammatory medicine), so if these two drugs are available, this organisation recommends that patients choose one of them at the base of cost “, availability and doctor's recommendation”. However, it is not recommended that these two drugs be taken at the same time.

The recommendation to use these drugs is made from new data from seven studies, including 4,000 patients with COVID-19 with mild, severe and critical infections.

In update of guidelines for treating COVID-19, O experts The U.S. has recommended against using two ruxholitinib and tophacitinebe drugs for patients with COVID-19 seriously or critical conditions, as studies have not found that patients can benefit from them and are in danger of serious side effects.

Also, in this new guideline, WHO has made a conditional recommendation to use modern monochlonal antibody in patients who have not developed serious coronary diseases, and this type of treatment can only be used in those who are at high risk of hospitalization, as O said. BSH, patients who are not in serious condition have no major benefits from this treatment.

A similar recommendation has been made to the next drug of monochlonal antibodies (Casirib-imdevimab), as experts estimated that there is still no data to recommend this kind of treatment and their “efficiency against new variants, such as Omitron, is still unclear”.

The recommended drugs today are added to the list of treatment for COVIDD-19, which includes the use of block receptors and cortichosteroids with systematic action for patients who are seriously ill and critical. Also, WHO has earlier made recommendation for conditioning use of monochlonal casírib-imdevimab antibodies to certain patients.

Since the outbreak of pandemic in late 2019, reports Johns Hopkins University reports worldwide have recorded over 319 million cases and over 5.5 million deaths.